An EU group has issued long-awaited guidance on the key aspects that drug companies should consider when initiating and conducting complex clinical trials, which are fast gaining ground as a way to support the development of personalized medicines. The guideline explains the different approaches that sponsors should follow when filing a clinical trial application or requesting substantial amendments for a complex trial as compared to a conventional trial.
The guideline has been issued by the Clinical Trials Facilitation and Coordination Group (CTFG), which functions under the aegis of...